title: Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors.
abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation, systemic inflammation, and immunological abnormalities. Because cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 play a major role in the development of RA, their targeting could constitute a reasonable novel therapeutic strategy for treating RA. Indeed, worldwide clinical trials of TNF inhibiting biologic disease modifying antirheumatic drugs (bDMARDs) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti-human IL-6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bDMARDs to treat moderate to severe active RA in patients with an inadequate response to synthetic disease modifying antirheumatic drugs (sDMARDs). Although bDMARDs have elicited to a paradigm shift in the treatment of RA due to the prominent efficacy that had not been previously achieved by sDMARDs, a substantial percentage of patients failed primary or secondary responses to bDMARD therapy. Because RA is a heterogeneous disease in which TNF-α and IL-6 play overlapping but distinct pathological roles, further studies are required to determine the best use of TNF inhibitors and tocilizumab in individual RA patients.
authors.affiliation: Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan ; Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hishitani
authors.affiliation: Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan ; Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ogata
keywords: adalimumab; biologic; interleukin-6; rheumatoid arthritis
references.citation: Lancet. 2007 Dec 1;370(9602):1861-74
references.pmid: 17570481
references.citation: Mod Rheumatol. 2010 Apr;20(2):130-3
references.pmid: 19898919
references.citation: Ann Rheum Dis. 2012 Nov;71(11):1820-6
references.pmid: 22504558
references.citation: J Med Econ. 2012;15(3):576-85
references.pmid: 22313326
references.citation: Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54
references.pmid: 23983039
references.citation: Joint Bone Spine. 2013 Jul;80(4):386-92
references.pmid: 23141718
references.citation: Ann Rheum Dis. 2013 Jan;72(1):43-50
references.pmid: 22562983
references.citation: J Rheumatol. 2013 Jun;40(6):768-80
references.pmid: 23457383
references.citation: Semin Arthritis Rheum. 2010 Jun;39(6):425-41
references.pmid: 20223500
references.citation: J Rheumatol. 2014 Jan;41(1):15-23
references.pmid: 24187110
references.citation: Ann Rheum Dis. 2015 Apr;74(4):694-702
references.pmid: 24368514
references.citation: Clin Rheumatol. 2014 Jan;33(1):39-47
references.pmid: 24057092
references.citation: Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76
references.pmid: 23218430
references.citation: Mod Rheumatol. 2014 Jan;24(1):137-43
references.pmid: 24261770
references.citation: Immunotherapy. 2013 Jul;5(7):695-7
references.pmid: 23829620
references.citation: Lancet. 2013 May 4;381(9877):1541-50
references.pmid: 23515142
references.citation: Lancet. 2008 Mar 22;371(9617):987-97
references.pmid: 18358926
references.citation: Ann Rheum Dis. 2014 Jan;73(1):69-74
references.pmid: 23904473
references.citation: Arthritis Res Ther. 2011;13(5):R141
references.pmid: 21884601
references.citation: Ann Rheum Dis. 2011 Aug;70(8):1507-10
references.pmid: 21551509
references.citation: Rheumatology (Oxford). 2012 Oct;51(10):1860-9
references.pmid: 22753773
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: Best Pract Res Clin Rheumatol. 2011 Aug;25(4):549-67
references.pmid: 22137924
references.citation: N Engl J Med. 2011 Dec 8;365(23):2205-19
references.pmid: 22150039
references.citation: Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42
references.pmid: 22438671
references.citation: Ann Intern Med. 1999 Mar 16;130(6):478-86
references.pmid: 10075615
references.citation: Ann Rheum Dis. 2008 Nov;67(11):1516-23
references.pmid: 18625622
references.citation: Amyloid. 2011 Mar;18(1):25-8
references.pmid: 21284495
references.citation: Scand J Rheumatol. 2014;43(3):177-83
references.pmid: 24354438
references.citation: Mod Rheumatol. 2014 May;24(3):405-9
references.pmid: 24252016
references.citation: Rheumatology (Oxford). 2012 Jan;51(1):60-8
references.pmid: 21515629
references.citation: Arthritis Res Ther. 2013 Oct 02;15(5):R141
references.pmid: 24286116
references.citation: Ann Rheum Dis. 2013 Dec;72(12):1897-904
references.pmid: 23918035
references.citation: Ann Rheum Dis. 2004 Feb;63(2):149-55
references.pmid: 14722203
references.citation: Biologics. 2012;6:155-61
references.pmid: 22848148
references.citation: Swiss Med Wkly. 2012 May 31;142:w13580
references.pmid: 22653707
references.citation: Ann Rheum Dis. 2013 Mar;72(3):464-5
references.pmid: 23148310
references.citation: Rheumatology (Oxford). 2013 Dec;52(12):2127-35
references.pmid: 23946435
references.citation: J Med Econ. 2012;15(2):340-51
references.pmid: 22168785
references.citation: Int J Biol Sci. 2013;9(3):279-88
references.pmid: 23493630
references.citation: Ann Rheum Dis. 2010 Jan;69(1):88-96
references.pmid: 19297346
references.citation: Arthritis Rheum. 2012 Aug;64(8):2499-503
references.pmid: 22488116
references.citation: Ann Rheum Dis. 2009 Jul;68(7):1235-6
references.pmid: 19525413
references.citation: Arthritis Rheum. 2008 Oct;58(10):2968-80
references.pmid: 18821691
references.citation: Ann Rheum Dis. 2009 Jun;68(6):789-96
references.pmid: 19066176
references.citation: Expert Rev Clin Immunol. 2010 Nov;6(6):843-54
references.pmid: 20979549
references.citation: Curr Med Res Opin. 2011 Oct;27(10):1885-97
references.pmid: 21848493
references.citation: Rev Esp Salud Publica. 2013 Jul-Aug;87(4):343-50
references.pmid: 24100773
references.citation: Cancer Res. 1993 Feb 15;53(4):851-6
references.pmid: 8428365
references.citation: Arthritis Rheum. 2011 May;63(5):1255-64
references.pmid: 21305508
references.citation: J Clin Pharm Ther. 2012 Jun;37(3):301-7
references.pmid: 21831256
references.citation: Rheumatology (Oxford). 2011 Nov;50(11):2093-9
references.pmid: 21890622
references.citation: Ann Rheum Dis. 2011 Feb;70(2):266-71
references.pmid: 21097801
references.citation: Ann Rheum Dis. 2007 Sep;66(9):1162-7
references.pmid: 17485422
references.citation: Immunotherapy. 2013 Mar;5(3):265-99
references.pmid: 23444956
references.citation: Clin Rheumatol. 2011 Nov;30(11):1471-4
references.pmid: 21833686
references.citation: J Rheumatol. 2012 Jan;39(1):63-72
references.pmid: 22045836
references.citation: Arthritis Rheum. 2009 May 15;61(5):560-8
references.pmid: 19405000
references.citation: Arthritis Rheum. 2006 Jan;54(1):26-37
references.pmid: 16385520
references.citation: Lancet. 2004 Feb 28;363(9410):675-81
references.pmid: 15001324
references.citation: Arthritis Rheum. 2008 Nov;58(11):3319-29
references.pmid: 18975346
references.citation: Clin Exp Immunol. 2013 Mar;171(3):237-42
references.pmid: 23379428
references.citation: Arthritis Rheum. 2008 Dec;58(12):3710-9
references.pmid: 19035481
references.citation: Lancet. 1999 Dec 4;354(9194):1932-9
references.pmid: 10622295
references.citation: Ann N Y Acad Sci. 2009 Sep;1173:837-46
references.pmid: 19758236
references.citation: Mod Rheumatol. 2009;19(1):12-9
references.pmid: 18979150
references.citation: Arthritis Rheum. 2011 Mar;63(3):609-21
references.pmid: 21360490
references.citation: Biologics. 2012;6:429-64
references.pmid: 23269860
references.citation: Nat Med. 2013 Mar;19(3):322-8
references.pmid: 23396208
references.citation: Mod Rheumatol. 2013 Mar;23(2):276-83
references.pmid: 22669600
references.citation: Scand J Rheumatol. 2013;42(4):253-9
references.pmid: 23470089
references.citation: Arthritis Rheum. 2003 Aug;48(8):2122-7
references.pmid: 12905464
references.citation: Annu Rev Pharmacol Toxicol. 2012;52:199-219
references.pmid: 21910626
references.citation: Ann Rheum Dis. 2014 Mar;73(3):492-509
references.pmid: 24161836
references.citation: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794
references.pmid: 21328309
references.citation: Arthritis Rheum. 2010 Jan;62(1):22-32
references.pmid: 20039405
references.citation: J Immunol. 2002 Aug 1;169(3):1459-66
references.pmid: 12133972
references.citation: Arthritis Rheum. 2009 Jul;60(7):1884-94
references.pmid: 19565495
references.citation: Ann Rheum Dis. 2012 Jul;71(7):1134-42
references.pmid: 22294625
references.citation: Clin Rheumatol. 1999;18(2):122-3
references.pmid: 10357116
references.citation: J Clin Invest. 2004 May;113(9):1271-6
references.pmid: 15124018